321 related articles for article (PubMed ID: 23199529)
41. Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis.
Catasus L; Gallardo A; Cuatrecasas M; Prat J
Mod Pathol; 2009 Apr; 22(4):522-9. PubMed ID: 19234438
[TBL] [Abstract][Full Text] [Related]
42. Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations.
Secq V; Villeret J; Fina F; Carmassi M; Carcopino X; Garcia S; Metellus I; Boubli L; Iovanna J; Charpin C
Br J Cancer; 2014 Feb; 110(4):1045-52. PubMed ID: 24423920
[TBL] [Abstract][Full Text] [Related]
43. Circulating-free DNA Mutation Associated with Response of Targeted Therapy in Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer.
Ye Q; Qi F; Bian L; Zhang SH; Wang T; Jiang ZF
Chin Med J (Engl); 2017 Mar; 130(5):522-529. PubMed ID: 28229982
[TBL] [Abstract][Full Text] [Related]
44. PIK3CA mutations in endometrial carcinomas in Chinese women: phosphatidylinositol 3'-kinase pathway alterations might be associated with favorable prognosis.
Dong Y; Yang X; Wong O; Zhang X; Liang Y; Zhang Y; Wong W; Nong L; Liao Q; Li T
Hum Pathol; 2012 Aug; 43(8):1197-205. PubMed ID: 22209294
[TBL] [Abstract][Full Text] [Related]
45. Functional role of ALK-related signal cascades on modulation of epithelial-mesenchymal transition and apoptosis in uterine carcinosarcoma.
Inoue H; Hashimura M; Akiya M; Chiba R; Saegusa M
Mol Cancer; 2017 Feb; 16(1):37. PubMed ID: 28193280
[TBL] [Abstract][Full Text] [Related]
46. NEDD4 ubiquitin ligase is a putative oncogene in endometrial cancer that activates IGF-1R/PI3K/Akt signaling.
Zhang Y; Goodfellow R; Li Y; Yang S; Winters CJ; Thiel KW; Leslie KK; Yang B
Gynecol Oncol; 2015 Oct; 139(1):127-33. PubMed ID: 26193427
[TBL] [Abstract][Full Text] [Related]
47. Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus.
Winter WE; Seidman JD; Krivak TC; Chauhan S; Carlson JW; Rose GS; Birrer MJ
Gynecol Oncol; 2003 Oct; 91(1):3-8. PubMed ID: 14529656
[TBL] [Abstract][Full Text] [Related]
48. Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 Chinese patients with lung adenocarcinoma.
Zhao M; Zhan C; Li M; Yang X; Yang X; Zhang Y; Lin M; Xia Y; Feng M; Wang Q
J Thorac Dis; 2018 Jan; 10(1):398-407. PubMed ID: 29600072
[TBL] [Abstract][Full Text] [Related]
49. Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma.
Ollikainen M; Gylling A; Puputti M; Nupponen NN; Abdel-Rahman WM; Butzow R; Peltomäki P
Int J Cancer; 2007 Aug; 121(4):915-20. PubMed ID: 17471559
[TBL] [Abstract][Full Text] [Related]
50. Antagonistic functional duality of cancer genes.
Stepanenko AA; Vassetzky YS; Kavsan VM
Gene; 2013 Oct; 529(2):199-207. PubMed ID: 23933273
[TBL] [Abstract][Full Text] [Related]
51. Expression profiling of 22 genes involved in the PI3K-AKT pathway identifies two subgroups of high-grade endometrial carcinomas with different molecular alterations.
Catasus L; D'Angelo E; Pons C; Espinosa I; Prat J
Mod Pathol; 2010 May; 23(5):694-702. PubMed ID: 20173732
[TBL] [Abstract][Full Text] [Related]
52. HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy.
Ha SY; Lee J; Jang J; Hong JY; Do IG; Park SH; Park JO; Choi MG; Sohn TS; Bae JM; Kim S; Kim M; Kim S; Park CK; Kang WK; Kim KM
Int J Cancer; 2015 Apr; 136(7):1629-35. PubMed ID: 25157953
[TBL] [Abstract][Full Text] [Related]
53. Racial differences in oncogene mutations detected in early-stage low-grade endometrial cancers.
Cote ML; Atikukke G; Ruterbusch JJ; Olson SH; Sealy-Jefferson S; Rybicki BA; Alford SH; Elshaikh MA; Gaba AR; Schultz D; Haddad R; Munkarah AR; Ali-Fehmi R
Int J Gynecol Cancer; 2012 Oct; 22(8):1367-72. PubMed ID: 23013731
[TBL] [Abstract][Full Text] [Related]
54. Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.
Mackay HJ; Eisenhauer EA; Kamel-Reid S; Tsao M; Clarke B; Karakasis K; Werner HM; Trovik J; Akslen LA; Salvesen HB; Tu D; Oza AM
Cancer; 2014 Feb; 120(4):603-10. PubMed ID: 24166148
[TBL] [Abstract][Full Text] [Related]
55. Clinicopathological and molecular analyses of uterine carcinosarcomas using next-generation sequencing: A single-center experience.
Erdogan EG; Yalta TD; Can N; Süt N; Taştekin E; Usta U; Puyan FÖ; Usturalı Keskin FE; Kurt BB
Indian J Pathol Microbiol; 2023; 66(3):449-455. PubMed ID: 37530323
[TBL] [Abstract][Full Text] [Related]
56. Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors.
Millis SZ; Ikeda S; Reddy S; Gatalica Z; Kurzrock R
JAMA Oncol; 2016 Dec; 2(12):1565-1573. PubMed ID: 27388585
[TBL] [Abstract][Full Text] [Related]
57. A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas.
Dias-Santagata D; Lam Q; Bergethon K; Baker GM; Iafrate AJ; Rakheja D; Hoang MP
Mod Pathol; 2011 Jul; 24(7):974-82. PubMed ID: 21423156
[TBL] [Abstract][Full Text] [Related]
58. Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer.
Nakajima H; Ishikawa Y; Furuya M; Sano T; Ohno Y; Horiguchi J; Oyama T
Breast Cancer; 2014 Jan; 21(1):66-74. PubMed ID: 22481575
[TBL] [Abstract][Full Text] [Related]
59. HER2 Gene Protein Assay: A Robust Tool for Evaluating HER2 Status and Intratumoral Heterogeneity in Endometrial Cancers.
Shafi S; Nitta H; Shah M; Challa B; Parwani AV; Li Z
Am J Clin Pathol; 2023 May; 159(5):464-473. PubMed ID: 36857635
[TBL] [Abstract][Full Text] [Related]
60. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).
English DP; Bellone S; Cocco E; Bortolomai I; Pecorelli S; Lopez S; Silasi DA; Schwartz PE; Rutherford T; Santin AD
Am J Obstet Gynecol; 2013 Nov; 209(5):465.e1-9. PubMed ID: 23891627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
